FDA Alert – Artificial Tears

On Feb. 3, the US Food and Drug Administration (FDA) issued a warning statement to consumers and health care practitioners to not purchase and to immediately stop using EzriCare Artificial Tears and Delsam Pharma’s Artificial Tears, due to potential bacterial contamination. Both products have been voluntarily recalled.

The Centers for Disease Control (CDC) has developed related resources for health care providers:

- - Sample Customizable Patient Notification Letter
  - Provider Talking Points about Artificial Tears

The CDC continues to investigate the multistate outbreak of an extensively drug-resistant strain of Pseudomonas aeruginosa associated with artificial tears.

Please refer to OMIC's Copyright and Disclaimer regarding the contents on this website

Six reasons OMIC is the best choice for ophthalmologists in America.

Consistent return of premium.

Publicly-traded insurance companies exist to make profits for shareholders while physician-owned carriers often return profits to their policyholders. Don’t underestimate this benefit; it can add up to tens of thousands of dollars over the course of your career. OMIC has one of the most generous dividend programs for ophthalmologists and has returned more than $90 Million to our members through dividends.

Policyholder Services

FDA Alert – Artificial Tears